EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 3.0

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials

Ashraf Alazzoni, Ayman Al-Saleh, Sanjit S Jolly

Thrombosis · 2012

DOI: 10.1155/2012/126369 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Thrombosis, 2012. Verfasst von Ashraf Alazzoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medine and Cardiology, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada L8L 2X2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Individual randomized trials have suggested that everolimus-eluting stents may have improved clinical outcomes compared to paclitaxel-eluting stents, but individual trials are underpowered to examine outcomes such as mortality and very late stent thrombosis.

Methods

Medline, Cochrane, and conference proceedings were searched for randomized trials comparing everolimus versus paclitaxel-eluting stents for percutaneous coronary intervention.

Results

6792 patients were included from 4 randomized controlled trials. Stent thrombosis was reduced with everolimus stents versus paclitaxel stents (0.7% versus 2.3%; OR: 0.32; CI: 0.20–0.51; P < 0.00001 ). The reductions in stent thrombosis were observed in (i) early stent thrombosis (within 30 days) (0.2% versus 0.9%; OR: 0.24; P = 0.0005 ), (ii) late (day 31–365) (0.2% versus 0.6%; OR: 0.32; P = 0.01 ), and (iii) very late stent thrombosis (>365 days) (0.2% versus 0.8%; OR: 0.34; P = 0.009 ). The rates of cardiovascular mortality were 1.2% in everolimus group and 1.6% in paclitaxel group (OR: 0.85; P = 0.43 ). Patients receiving everolimus-eluting stents had significantly lower myocardial infarction events and target vessel revascularization as compared to paclitaxel-eluting stents.

Interpretation

Everolimus compared to paclitaxel-eluting stents reduced the incidence of early, late, and very late stent thrombosis as well as target vessel revascularization.

Autor:innen und Institutionen

  • Departments of Medine and Cardiology, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada L8L 2X2.

Zitieren

APA

Alazzoni, A., Al-Saleh, A., & Jolly, S. S. (2012). Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials. Thrombosis. https://doi.org/10.1155/2012/126369

Vancouver

Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials. Thrombosis. 2012. doi:10.1155/2012/126369

BibTeX
@article{Alazzoni2012,
  author = {Alazzoni, Ashraf and Al-Saleh, Ayman and Jolly, Sanjit S},
  title = {Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials},
  journal = {Thrombosis},
  year = {2012},
  doi = {10.1155/2012/126369}
}
Kostenlos starten →